Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial.

@article{Burch2005PhaseIS,
  title={Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial.},
  author={Patrick A. Burch and James A. Mailliard and David W. Hillman and Edith A. Perez and James E. Krook and Kendrith M. Rowland and Michael H. Veeder and Michael W. Cannon and James N. Ingle},
  journal={American journal of clinical oncology},
  year={2005},
  volume={28 2},
  pages={195-200}
}
BACKGROUND This 2-stage, phase II cooperative group trial examined the efficacy and toxicity of 1000 mg/m2 gemcitabine plus 25 mg/m2 cisplatin weekly for 3 weeks and repeated every 28 days for patients with previously treated metastatic breast cancer. METHODS Eligible patients had to have measurable metastatic disease. Progression on prior treatment with at least 1 chemotherapy program for metastatic disease and 1 prior anthracycline and/or taxane-containing regimen in either the metastatic… CONTINUE READING
16 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Similar Papers

Loading similar papers…